Comparison of Treatment and Prognosis Between Follicular Variant Papillary Thyroid Carcinoma and Classical Papillary Thyroid Carcinoma

Abstract

This cohort study evaluated the associations of different treatments with the prognosis of follicular variant papillary thyroid carcinoma (FVPTC) and classical papillary thyroid carcinoma (CPTC) patients. The data of 69034 PTC patients were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. The 5-year mortality of CPTC and FVPTC patients receiving surgery, radiation and combination therapy were compared. The univariable and multivariable cox proportional risk models explored the associations between different treatments and the 5-year mortality in CPTC and FVPTC patients. The 5-year mortality of CPTC patients was 2.81% and FVPTC patients was 2.47%. Compared with CPTC receiving lobectomy and/or isthmectomy, those not receiving surgery were associated with increased risk of 5-year mortality [Hazards ratio (HR)=3.27, 95% confidence interval (CI): 2.55–4.20] while total thyroidectomy was correlated with reduced risk of 5-year mortality (HR=0.67, 95%CI: 0.55–0.80). Radioactive iodine (RAI) was linked with decreased risk of 5-year mortality in CPTC patients (HR=0.57, 95%CI: 0.50–0.65). CPTC patients undergoing both surgery and radiation were related to decreased risk of 5-year mortality compared with those receiving surgery only (HR=0.55, 95%CI: 0.48–0.63). CPTC patients receiving neither surgery nor radiation (HR=4.53, 95%CI: 3.72–5.51) or those receiving radiation (HR=1.98, 95%CI: 1.13–3.48) were correlated with elevated risk of 5-year mortality. The elevated risk of 5-year mortality in FVPTC patients was reduced in those undergoing RAI (HR=0.63, 95%CI: 0.51–0.76). In conclusion, combination therapy was associated with decreased risk of 5-year mortality in CPTC and FVPTC patients, which might provide a reference for the management of these patients.

Key words

follicular variant papillary thyroid carcinoma - classical papillary thyroid carcinoma - surgery - radiation

Publication History

Received: 12 July 2023

Accepted after revision: 06 September 2023

Article published online:
09 October 2023

• References

• 1 Shao C, Li Z, Zhang C. et al. Optical diagnostic imaging and therapy for thyroid cancer. Mater Today Bio 2022; 17: 100441
• 2 Issa PP, Albuck AL, Hossam E. et al. The diagnostic performance of ultrasonography in the evaluation of extrathyroidal extension in papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Mol Sci 2022; 24
• 3 Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach. Endocrinol Metab (Seoul, Korea) 2022; 37: 703-718
• 4 Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer 2016; 23: 313-322
• 5 Henke LE, Pfeifer JD, Baranski TJ. et al. Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma. Endocr Connect 2018; 7: 1226-1235
• 6 Tunca F, Sormaz IC, Iscan Y. et al. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma. J Edocrinol Invest 2015; 38: 1327-1334
• 7 Raffaelli M, Tempera SE, Sessa L. et al. Total thyroidectomy versus thyroid lobectomy in the treatment of papillary carcinoma. Gland Surg 2020; 9: S18-S27
• 8 Tang J, Kong D, Bu L. et al. Surgical management for follicular variant of papillary thyroid carcinoma. Oncotarget 2017; 8: 79507-79516
• 9 Sun Y, Gong J, Guo B. et al. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer. Oral Oncol 2018; 87: 152-157
• 10 Fujiwara T, Yoshizawa A, Mizuta M. et al. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?. Auris Nasus Larynx 2021; 48: 148-153
• 11 Simões-Pereira J, Mourinho N, Ferreira TC. et al. Avidity and outcomes of radioiodine therapy for distant metastasis of distinct types of differentiated thyroid cancer. J Clin Endocrinol Metab 2021; 106: e3911-e3922
• 12 Wang X, Zheng X, Zhu J. et al. Radioactive iodine therapy may not improve disease-specific survival in follicular variant papillary thyroid cancer without distant metastasis: a propensity score-matched analysis. Head Neck 2021; 43: 1730-1738
• 13 Chen J, Chen Q, Deng Y. et al. Development and validation of prognostic nomograms for periampullary neuroendocrine neoplasms: a SEER database analysis. Curr Oncol (Toronto, Ont) 2022; 30: 344-357
• 14 Zhang D, Tang J, Kong D. et al. Impact of gender and age on the prognosis of differentiated thyroid carcinoma: a retrospective analysis based on SEER. Horm Cancer 2018; 9: 361-370
• 15 Lang BH, Lo CY, Chan WF. et al. Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg 2006; 30: 752-758
• 16 Suman P, Razdan SN, Wang CE. et al. Thyroid lobectomy for T1b-T2 papillary thyroid cancer with high-risk features. J Am College Surg 2020; 230: 136-144
• 17 Wu Z, Han L, Li W. et al. Which is preferred for initial treatment of papillary thyroid cancer, total thyroidectomy or lobotomy?. Cancer Med 2021; 10: 1614-1622
• 18 Vasileiadis I, Boutzios G, Karalaki M. et al. Papillary thyroid carcinoma of the isthmus: total thyroidectomy or isthmusectomy?. Am J Surg 2018; 216: 135-139
• 19 Wang X, Zhu J, Li Z. et al. The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer. PloS One 2020; 15: e0234843
• 20 Ruel E, Thomas S, Dinan M. et al. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab 2015; 100: 1529-1536
• 21 Tian T, Qi Z, Huang S. et al. Radioactive iodine therapy decreases the recurrence of intermediate-risk PTC with low thyroglobulin levels. J Clin Endocrinol Metab 2023; 108: 2033-2041
• 22 Sun YQ, Sun D, Zhang X. et al. Radioiodine adjuvant therapy in differentiated thyroid cancer: an update and reconsideration. Front Endocrinol 2022; 13: 994288
• 23 Haugen BR, Alexander EK, Bible KC. et al. 2015; American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1-133
• 24 MacKinney EC, Kuchta KM, Winchester DJ. et al. Overall survival is improved with total thyroidectomy and radiation for male patients and patients older than 55 with T2N0M0 Stage 1 classic papillary thyroid cancer. Surgery 2022; 171: 197-202
• 25 Holoubek SA, MacKinney EC, Khokar AM. et al. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm. Surgery 2022; 171: 203-211